Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hope it's not another 3 years,
if you like Marxist ideology
We all know how communism ends up....millions of dead people, failed economies and horrible living conditions....
Please help us understand how they are one of the leaders with some facts other than someone on a MB pumping a stock..
I am not sure the last time someone actually made money selling patents.
They have one facility that cannot meet the demands of one large commercial application.
they have done nothing but spend money and pad their own bank accounts
You seem to be fixated on the past, in particular, whatever
you think reflects badly on PSTI's prospects.
Let's remember, this is a small biotech, it needs money,
it has to navigate a treacherous financial and regulatory
environment, and overall, it's been doing well enough to
survive and push their technology forward.
"Two steps forward, one step back" said my favorite philosopher, Vladimir Lenin.
The direction is forward!
....just 5.6 million more to go....then the stock can really tank
They are filling the "institutional ownership" dilution.....there is no other demand
May not be original, but that is the only thing they have delivered on in 10 years.....
Now they can fund those bonuses....
what am I missing.......
A combination of new funds (shelf) AND a strong forward momentum
in moving PAD/PLX toward commercialization is positive. There may
be a few days of downward pressure on the pps, but I've seen that
reverse very quickly.
The important thing is for management to provide guidance as to
how the money will be used to advance the cause. I'm not worried
at this time.
My intent in analyzing the manufacturing facility was an attempt
to inject a reality based perspective on the valuation of this asset
Are you the twin?
Are you saying this entire issue is a non-issue...if yes...I tend to agree.
You really do belabor the irrelevant!
We had a great day, enjoy, stop fussing with nonsense.
1% of me thinks it is something wrong with the techonology
Placenta-Derived Adherent Stromal Cells Improve Diabetes Mellitus-Associated Left Ventricular Diastolic Performance
"The aims of the present study were to investigate whether intravenous (i.v.) application of PLX could improve diabetes mellitus-associated impaired LV diastolic relaxation at the early onset of diabetic cardiomyopathy and to analyze underlying mechanisms."
Glicky must have under delivered as AUPH is plunging...
For the critics, I think that it is really hard to judge the leadership as a failure. The stem cell market is unchartered territory and there have surely been mistakes along the way. However, they are pioneers and there isn't any textbook on how to stand up a game changing company in unknown territory.
For the cheerleaders. Great technology, product, and I agree on the doorstep of advancement. Don't be so celebratory and naive around management though. Zami was an excellent visionary and strategist to go after the 3D technology and placental source, but the naysayers do have some good points about bringing in industry experience and more business horse power. Management does matter!
yaki twins may be over their heads
Just because it's negative, doesn't mean it's not an important discussion.
Glad to see your return Blue. Well said.
Down over a dollar...
No product approval, no partnership, no contracts or sales, no revenue.
...nothing more than a list of broken promises
NOTHING has changed over the 4+ years and based on historical data,
nothing will change over the next 4 years
Hate the game and also hate the player that doesn't play honorably.
we have been listening to their false promises for over 7 years.
Today’s news is good I guess, but all it says to me is that they
have another pipe dream ten years down the road.
Pluristem's PLX Cells in Improving Cardiac Function in Diabetes
They will deserve every inch of that boot if they don't come through
It has been a long time coming for some of us. I'm right
there with you in the length of time I've invested in Pluristem.
Been in 7-8 years and if we can’t get a nice cushion above $2 by mid-December I will raise hell.
I will be in route to Haifa demanding answers in person,
with a size 12 boot ready to be shoved up where the sun don’t shine.
Could also help a couple more professional pumpers like FDA
Get over it Jess. Some day your picks will be winners....
Let's see if I can understand your perspective on PSTI:
1. You love PSTI, .. but then
2. You hate PSTI, .. then
3. You love PSTI, .. It's a 60+ bagger, .. but then
4. Hate PSTI ("the twins the twins seem best at...missing deadlines"), ... then
5. Hate PSTI ... again!
6. .... well, I could go on and on and on.
7. .... etc., etc.....
I'm beginning to miss "horsesho"!
Experience
I see a lot of sell off coming
I'm comfortable that AUPH's compound will be approved for LN
I could do it for less with much greater margins. That's how great business leader run companies right.
Sickening. Only thing I can think of is their technology isn't as good as they say it is.
I'm clueless eh Allo? Lmao
We are getting hammered today, why?
Shorts are in control and ADXS remains impotent. The question is why?
Personally, I believe this investment is at an EXTREMELY risky juncture because we have no clue how good Lombardo is or what he's going to make happen.
Very impressive, not just the cash infusion (which is itself very nice)
but the recognition of Pluristem's technology as a worthy target of
this sort of research, AND the advantage, from an approval point of
view, of being able to track the therapeutic progress after cell infusion.
from announcement:
The goal of the nTRACK project, initiated and led scientifically by Prof. Rachela Popovtzer of Bar-Ilan University in Israel, is to develop a safe, scalable, and highly sensitive nanotechnology-based imaging approach to enable non-invasive, whole body monitoring of injected stem cells in humans, thereby providing early predictions of cellular therapy treatment outcomes. The nTRACK consortium will utilize Pluristem’s PLX-PAD cells to predict treatment success for muscle regeneration following a gastrocnemius muscle injury. Final approval of the grant is subject to the finalization of the consortium and Horizon 2020 grant agreements.